Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cancer vaccine MUC 1 - Vaxil Biotehrapeutics

Next Previous
Drug Profile

Cancer vaccine MUC 1 - Vaxil Biotehrapeutics

Alternative Names: Anti-MUC1 Sp therapeutic vaccine - Vaxil Biotherapeutics; Anti-MUC1 therapeutic cancer vaccine (ImMucin) - Vaxil BioTherapeutics; Cancer vaccine MUC-1; ImMucin; MUC-1; VXL-100

Latest Information Update: 28 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaxil BioTherapeutics
  • Developer Hadassah Medical School; Vaxil BioTherapeutics
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Breast cancer; Multiple myeloma
  • No development reported Haematological malignancies; Solid tumours

Most Recent Events

  • 28 Oct 2025 No recent reports of development identified for preclinical development in Solid-tumours in Israel (Parenteral, Injection)
  • 28 Oct 2025 No recent reports of development identified for preclinical development in Solid-tumours(Combination therapy) in Israel (Parenteral, Injection)
  • 29 Sep 2021 Cancer vaccine MUC 1 is still in preclinical trials for Solid tumours in Israel

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top